That's wild when someone is pandering for a bear position. There is usually no shortage of people offering dire warnings. The strongest objection I've seen so far is the FDA's lengthy process potentially delaying US approval for ARTH. To me, this is not so much of a comment on the commercial viability of ARTH than it is a comment on the bloated and bureaucratic structure of the FDA. It is not just ARTH that is subject to the onerous FDA approval process, but it applies equally to every medical company. Back in the day, we used to call them bean-counters in the corporate world.
News 
Market Data 
Discover 
